Skip to main content
PLOS Medicine logoLink to PLOS Medicine
. 2024 Nov 20;21(11):e1004473. doi: 10.1371/journal.pmed.1004473

Economic, cultural, and social inequalities in potentially inappropriate medication: A nationwide survey- and register-based study in Denmark

Amanda Paust 1,2,*, Claus Vestergaard 1, Susan M Smith 3, Karina Friis 4, Stine Schramm 5, Flemming Bro 1,2, Anna Mygind 1, Nynne Bech Utoft 1, James Larkin 6, Anders Prior 1
PMCID: PMC11578507  PMID: 39565747

Abstract

Background

Potentially inappropriate medication (PIM) is associated with negative health outcomes and can serve as an indicator of treatment quality. Previous studies have identified social inequality in treatment but often relied on narrow understandings of social position or failed to account for mediation by differential disease risk among social groups. Understanding how social position influences PIM exposure is crucial for improving the targeting of treatment quality and addressing health disparities. This study investigates the association between social position and PIM, considering the mediation effect of long-term conditions.

Methods and findings

This cross-sectional study utilized data from the 2017 Danish National Health Survey, including 177,495 individuals aged 18 or older. Data were linked to national registers on individual-level.

PIM was defined from the STOPP/START criteria and social position was assessed through indicators of economic, cultural, and social capital (from Bourdieu’s Capital Theory). We analyzed odds ratios (ORs) and prevalence proportion differences (PPDs) for PIM using logistic regression, negative binomial regression, and generalized structural equation modeling. The models were adjusted for age and sex and analyzed separately for indicators of under- (START) and overtreatment (STOPP). The mediation analysis was conducted to separate direct and indirect effects via long-term conditions. Overall, 14.7% of participants were exposed to one or more PIMs, with START PIMs being more prevalent (12.5%) than STOPP PIMs (3.1%). All variables for social position except health education were associated with PIM in a dose-response pattern. Individuals with lower wealth (OR: 1.85 [95% CI 1.77, 1.94]), lower income (OR: 1.78 [95% CI 1.69, 1.87]), and lower education level (OR: 1.66 [95% CI 1.56, 1.76]) exhibited the strongest associations with PIM. Similar associations were observed for immigrants, people with low social support, and people with limited social networks. The association with PIM remained significant for most variables after accounting for mediation by long-term conditions. The disparities were predominantly related to overtreatment and did not relate to the number of PIMs. The study’s main limitation is the risk of reverse causation due to the complex nature of social position and medical treatment.

Conclusions

The findings highlight significant social inequalities in PIM exposure, driven by both economic, cultural, and social capital despite a universal healthcare system. Understanding the social determinants of PIM can inform policies to reduce inappropriate medication use and improve healthcare quality and equity.


Amanda Paust and colleagues leverage data from the 2017 Danish National Health Survey and linked to national registers to explore how economic, cultural, and social inequalities contribute to inappropriate medication prescribing.

Author summary

Why was this study done?

  • Potentially inappropriate medication (PIM) is linked to adverse health outcomes and indicates treatment quality issues.

  • Previous research has identified social inequalities in medical treatment but often relied on narrow definitions of social position and did not fully account for the mediation effect of long-term conditions.

  • There was a need to understand how broader aspects of social position, including economic, cultural, and social capital, influence PIM to inform policy and practice.

What did the researchers do and find?

  • This study utilized data from the 2017 Danish National Health Survey, including 177,495 individuals aged 18 and older, linked with national registers.

  • All variables for social position except health education were associated with PIM. Wealth, income, and education level exhibited the strongest associations with PIM, but similar associations were observed for immigrants, not living with other adults, low social support, and limited social networks.

  • The association with PIM remained significant for most variables after accounting for mediation by long-term conditions. The disparities were predominantly related to overtreatment and did not relate to the number of PIMs.

What do these findings mean?

  • The study highlights significant social inequalities in PIM exposure, suggesting that socioeconomic disparities in healthcare persist even in a universal healthcare system. Understanding these disparities can guide efforts to reduce inappropriate medication use and improve patient safety

  • The findings indicate that economic, cultural, and social capital are crucial determinants of treatment quality, with economic capital showing the strongest association.

  • The study’s main limitation is the risk of reverse causation due to the complex nature of social position and medical treatment.

Introduction

The use of medicines has increased worldwide due to an aging population and a higher prevalence of multimorbidity (≥2 long-term conditions). Half of the world population above age 60 years have multimorbidity, and although multiple medicines may be necessary, an increasing number of medications also increases the risk of adverse drug interactions and suboptimal medical treatment [1,2]. Potentially inappropriate medication (PIM) is often used as an indicator of medical treatment quality. It refers to the omission of appropriate medicines or the use of medicines that may pose more harm than benefit or may have safer alternatives [3]. PIM is associated with a higher risk of emergency visits, medication-related hospitalizations, lower quality of life, increased mortality, and substantial costs for individuals and society [4].

Additionally, social inequality in health is increasing [5]. This escalation is partly attributed to an uneven risk of suboptimal treatment between people with different positions in the social hierarchy (i.e., social positions) [6,7]. PIM serves as a critical measure of inequality in treatment. An inverse association between social position and PIM has already been established [8,9]. Yet, when investigating the connection, studies tend to ignore the differential disease risk between social groups, which mediates much of the association between social position and PIM [9]. Furthermore, investigations often fail to provide a nuanced reflection of the association, e.g., by using inadequate measures of social position [10], possibly due to limited data accessibility or few theoretical considerations [11]. For example, even though income may poorly reflect the economic situation in old age, accumulated wealth or similar measures are rarely used to capture social position [12]. Considering the mediating role of long-term conditions and using a theoretical lens and alternative data sources to define and operationalize social position may allow for a more exhaustive comprehension of how social position relates to suboptimal treatment, which can inform future research, interventions, and policy development.

A highly acknowledged theoretical framework for exploring social position is provided by Bourdieu [10,13]. According to this, social position is shaped by an individual’s access to resources (economic, cultural, and social capital) and how these resources are employed in different social fields [1418]. Thus, the association between social position and PIM could be related to different forms of capital. Moreover, Denmark has extensive national registers and surveys covering various health-related and social aspects. The civil registration number allows individual-level linkage between these data. The theoretical approach combined with the extensive data available in Denmark can be used to comprehensively examine the relationship between social position, medical treatment, and long-term conditions [19].

Hence, this study aimed to investigate the association between selected indicators of economic, cultural, and social capital with exposure to PIM, using Bourdieu’s capital theory and comprehensive national data, and considering the mediation by long-term conditions. To our knowledge, this is the first study to comprehensively explore these associations between social position and PIM. We hypothesized that all forms of capital would be inversely associated with the risk of receiving PIM and that multimorbidity would mediate some of the association.

Methods

Design

We performed a cross-sectional study based on information from the Danish National Health Survey and Danish National registers [19,20]. The RECORD criteria were used to conduct and report the study and are reported in S1 Table [21]. The study was based on a prospective protocol. Paust A. Social Inequality in Medical Treatment. protocols.io. 2024. doi: dx.doi.org/10.17504/protocols.io.ewov19wy2lr2/v1.

Population and setting

We included individuals aged ≥18 years who participated in the Danish National Health Survey 2017; this sample is known to constitute a nationally representative sample of the Danish population [20]. The invited population was selected by Statistics Denmark as a random sample of the adult Danish population for the survey year based on an algorithm to ensure geographic and demographic representativeness [20]. The authors did not have access to the database population used to create the study population. The questionnaire was sent to 321,349 individuals. A total of 183,372 individuals participated; 177,495 were eligible for inclusion (aged ≥18 years). The questionnaire data was collected from January 1, 2017 to May 19, 2017. The register data on demographics, morbidity, and social position [19] was collected on January 1, 2017. The register data on PIM was collected on May 19, 2017. Each variable’s response rates and missing data are reported in S2 and S3 Tables. Non-response analysis and data cleaning methods in the study population are elaborated elsewhere [22].

Data sources

Data on cohabitation, social network, and social support was collected from the Danish National Health Survey 2017 [20]. All remaining information was obtained from Danish registers [19]. The Danish Civil Registration System provided information on sex, age, immigration status, and mortality. Statistics Denmark provided data on education, income, and wealth. The Danish National Patient Register provided information on hospital diagnoses and procedure codes, and psychiatric hospital diagnoses were acquired from the Danish Psychiatric Central Research Register. The Danish National Prescription Register provided data on redemption dates and volumes of prescribed medications. Linking between patients and their general practice clinic was established through the Danish Patient List Database. All information was obtained at individual-level. This was pseudonymized and linked through the Danish personal identification number.

Outcome variables

Potentially inappropriate medication

PIM was defined from the STOPP/START criteria for inappropriate prescribing, developed by O’Mahony and colleagues [23], although modified to suit the Danish registers and the broader adult population [19]. The criteria included 29 indications for reducing or stopping medication (STOPP) and 10 indications for medication initiation (START) based on risk of drug–drug and drug–disease interactions [24]. The number of PIMs was calculated for all participants on May 19, 2017. The operationalization of PIM is described in S4 Table, and more details on methods can be found elsewhere [24,25]. Specific criteria were set for being identified as at risk for PIM dependent on the criteria in question (e.g., dependent on a specific condition or combination of conditions) [24].

Exposure variables

According to Bourdieu, social position can be divided into economic, cultural, and social capital [10]. These capital forms were operationalized from 8 indicators (Table 1). Detailed descriptions and argumentations for each indicator are provided in S5 Table. The relationship between variables is illustrated using a directed acyclic graph (DAG) [26] and presented in S1 Fig.

Table 1. Operationalization of social position.

Social position Indicator Measures
Economic capital Wealth quintile categories Aggregated household net wealth.
Income quintile categories Equivalent disposable household income.
Cultural capital Household education level Highest attained education level aggregated for household.
Healthcare-related education Having a healthcare-related education (regardless of level).
Immigration status Immigrant if both parents are foreign citizens or if born abroad. Descendant if at least one parent is immigrant.
Social capital Social network Interaction with friends, neighbors, colleagues, or family outside household.
Cohabitation Yes covers living with adults (≥ age 16), no covers not living with adult (≥ age 16).
Social support Having someone to support you or discuss problems with.

Operationalization elaborated in S5 Table.

Economic capital

We used register-based measures of aggregated household net wealth (quintile categories) and equivalent disposable household income (quintile categories) to describe economic capital. Wealth included the complete portfolio information, i.e., the value of bonds, stocks, cash in banks, real estate, mortgage loans, and the sum of other loans (excluding pension savings).

Cultural capital

To capture cultural capital, we employed 3 register-based measures: the highest attained education level aggregated for the household (primary and lower secondary, upper secondary, tertiary/bachelor/equivalent, or master/doctoral/equivalent), having a healthcare-related education regardless of the level (yes, no), and immigration status (Danish origin, immigrant, descendant).

Social capital

To capture social capital, we employed 3 survey items: a combined measure of social network, i.e., interaction with friends, neighbors, colleagues, or family outside the household (ranging from infrequent to frequent social contact), cohabitation (living with adult(s) (≥ age 16), not living with adult(s) (≥ age 16)), and social support, i.e., having someone to support you or discuss problems with (always, mostly, sometimes, never, or almost never).

Covariates

We included 3 register-based covariates, i.e., sex (male, female), age (using restricted cubic spline variables with 5 knots), and the number of long-term conditions (ranging from 0 to ≥5), as these are associated with both social position and PIM [27]. The Danish Multimorbidity Index was used to identify long-term conditions [28]. These conditions were defined as 39 physical and mental long-term diagnoses (see S6 Table) and identified from Danish registers [19].

Statistical analyses

For all independent variables, we calculated the count, the means, and the standard deviations for the number of START and STOPP PIMs in the population and estimated the prevalence proportion difference (PPD) adjusted for age and sex. Prevalence proportions were calculated as the number of PIMs per person; thereby, the numerator may exceed one.

To analyze the odds ratios (ORs) and the prevalence proportion ratios of PIM for indicators of social position, we employed logistic regression (logit) and negative binomial regression models (nbreg) and used generalized structural equation modeling (gsem) for mediation analyses. These analyses were conducted as complete case analyses using STATA software version 18. Model 1a used logit to estimate the OR between each indicator of social position and any PIM. Model 1b used nbreg to estimate the prevalence proportion ratios between social position and the number of PIMs, given that the individuals have at least one PIM. Both models were adjusted for age and sex. Model 2 presented the association between social position and PIM (i.e., 1a) stratified by START (2a) PIM and STOPP (2b) PIM, adjusted for age and sex. These models were also stratified by sex in model 3a and 3b. Model 4 examined the direct association between the indicators of social position and PIM (4a) and STOPP PIM (4b) (unmediated by long-term conditions) adjusted for age and sex. The mediation analysis was performed using gsem, separating the direct association from the association mediated by the number of long-term conditions (as illustrated in S1 Fig). This model was chosen to reduce the risk of introducing potential bias from adjusting for a mediator.

For all regression analyses, we included cluster-robust variance estimation to account for non-independence of observations due to participants sharing the same general practitioner (GP), i.e., clustering on GP level. This also considered geographical clustering of participants, as individuals sharing a GP generally share geographical location. Before conducting the analysis, we checked for possible collinearity between exposure variables and only saw substantial collinearity between indicators within the same capital form, e.g., wealth and income. Yet, variables from the same capital form did not enter the same analysis as all 8 indicators were analyzed separately. A brief study protocol informed the study, including hypothesis, main analysis, and specifications for variables, but amendments were made after internal and external review, adding post hoc analysis to the study. These include the mediation analysis (from the inclusion of DAGs based on internal review) and stratified analysis (suggested in external review). Besides, the study was planned as a 1-year follow-up study but was conducted as a cross-sectional study due to the risk of time-dependent bias.

Ethical considerations

The introductory letter for the survey underscored that participation was voluntary. Hence, upon completion of the questionnaire, respondents provided written consent to engage in the survey. Approval for the survey was obtained from the Danish Data Protection Agency. According to Danish law, this study could not be considered for ethical approval as it did not include human biological material [29]. The study adheres to the principles outlined in the Declaration of Helsinki [30].

Results

Descriptive data

The study sample consisted of 177,495 individuals with an average age of 53.1 years and 33.0% diagnosed with 2 or more long-term conditions (Table 2). Overall, 26,252 individuals in the study population were subjected to 1 or more PIMs at the time of the data collection, equivalent to 14.7% of the population. In total, 9.5% had 1 PIM, 3.0% had 2 PIMs, and 2.1% had 3 or more PIMs. Exposure to START PIMs (22,140/177,495 = 12.5%) was more common than exposure to STOPP PIMs (5,555/177,495 = 3.1%). Overall, 92.5% were of Danish origin, 86.2% had more than lower secondary education as the highest attained education level, and 7.8% had a healthcare-related education. In total, 33.6% of the study population reported having a limited social network, defined as having below-average frequency of social contact with people outside the household. In total, 20.9% lived alone or with child(ren) below age 16 years, and 13.0% reported low levels of social support, measured by never or rarely having someone to talk to when in need.

Table 2. Baseline characteristics of the total population and population exposed to PIM.

Characteristics All, n (%) START, n (%) STOPP, n (%)
N = 177,495 N = 22,140 N = 5,555
Covariates Sex Female 95,672 (53.9) 9,825 (44.4) 2,977 (53.6)
Male 81,823 (46.1) 12,315 (55.6) 2,578 (46.4)
Age 18–29 years 22,841 (12.9) 1,436 (6.5) 80 (1.4)
30–39 years 20,570 (11.6) 845 (3.8) 189 (3.4)
40–49 years 28,891 (16.3) 1,435 (6.5) 490 (8.8)
50–59 years 34,940 (19.7) 3,012 (13.6) 1,074 (19.3)
60–69 years 33,684 (19.0) 5,135 (23.2) 1,380 (24.8)
70–79 years 26,545 (15.0) 6,465 (29.2) 1,469 (26.4)
≥80 years 10,024 (5.6) 3,812 (17.2) 873 (15.7)
Number of long-term conditions 0 conditions 80,963 (45.6) 2,408 (10.9) 273 (4.9)
1 condition 37,971 (21.4) 3,918 (17.7) 740 (13.3)
2 conditions 23,110 (13.0) 4,131 (18.7) 933 (16.8)
3 conditions 15,264 (8.6) 3,765 (17.0) 1,018 (18.3)
4 conditions 9,363 (5.3) 2,948 (13.3) 923 (16.6)
≥5 conditions 10,824 (6.1) 4,970 (22.4) 1,668 (30.0)
Outcome Number of PIMs 0 151,402 (85.3) - -
1 16,887 (9.5) 14,171 (64.0) 5,160 (92.9)
2 5,397 (3.0) 4,651 (21.0) 368 (6.6)
3 3,096 (1.7) 3,318 (15.0)* 27 (0.5)*
4 584 (0.3)
≥5 129 (0.1)
Economic capital Wealth quintile categories 1 (least) 35,453 (20.0) 3,916 (17.7) 1,244 (22.4)
2 35,453 (20.0) 4,369 (19.7) 1,176 (21.2)
3 35,453 (20.0) 3,914 (17.7) 1,055 (19.0)
4 35,453 (20.0) 4,554 (20.6) 1,021 (18.4)
5 (most) 35,453 (20.0) 5,376 (24.3) 1,057 (19.0)
Income quintile categories 1 (least) 35,483 (20.0) 6,043 (27.3) 1,623 (29.2)
2 35,483 (20.0) 5,671 (25.6) 1,459 (26.3)
3 35,483 (20.0) 4,020 (18.2) 951 (17.1)
4 35,483 (20.0) 3,333 (15.1) 812 (14.6)
5 (most) 35,482 (20.0) 3,073 (13.9) 710 (12.8)
Cultural capital Immigration status Immigrant 1,406 (0.8) 123 (0.6) 17 (0.3)
Descendant 11,946 (6.7) 1,057 (4.8) 233 (4.2)
Danish origin 164,079 (92.5) 20,960 (94.7) 5,305 (95.5)
Household education level Primary and lower secondary 24,428 (13.8) 4,831 (22.0) 1,453 (26.4)
Upper secondary 78,076 (44.3) 10,191 (46.5) 2,540 (46.2)
Tertiary/bachelor 51,282 (29.1) 5,176 (23.6) 1,134 (20.6)
Master/doctoral 22,647 (12.8) 1,725 (7.9) 375 (6.8)
Healthcare education No 122,117 (92.0) 13,677 (63.0) 3,158 (58.0)
Yes 10,576 (7.8) 1,012 (4.7) 306 (5.6)
Social capital Social network 1 (infrequent) 7,634 (4.6) 1,234 (6.0) 406 (8.0)
2 47,961 (29.0) 6,232 (30.4) 1,600 (31.7)
3 80,619 (48.7) 9,900 (48.3) 2,349 (46.5)
4 (frequent) 29,221 (17.7) 3,116 (15.2) 692 (13.7)
Cohabitation No 34,291 (20.9) 5,480 (26.8) 1,589 (31.3)
Yes 130,110 (79.1) 14,991 (73.2) 3,488 (68.7)
Social support Never or almost never 6,973 (4.2) 1,121 (5.4) 330 (6.3)
Sometimes 14,774 (8.8) 1,918 (9.2) 597 (11.5)
Mostly 41,864 (25.1) 5,188 (24.8) 1,340 (25.8)
Always 103,495 (61.9) 12,722 (60.7) 2,935 (56.4)

*≥3 PIM

PIM, potentially inappropriate medication.

PIM and adjusted prevalence proportion difference

As demonstrated in Table 3, the mean number of PIM ranged from 0.12 (standard deviation [SD] 0.44) to 0.38 (SD 0.79) PIMs across groups with different economic, cultural, and social capital. While the mean number of START PIM was 0.19 (SD 0.58), the study population was exposed to 0.03 STOPP PIM (SD 0.19). When analyzing the age- and sex-adjusted PIM prevalence proportion, we found that the differences between those with the lowest and highest economic, cultural, and social capital amounted to 1 to 12 additional PIMs per 100 individuals for indicators of economic, cultural, and social capital; the least educated compared to the highest (PPD 0.09 [95% CI 0.07, 0.10]), the poorest compared to the wealthiest (PPD 0.12 [95% CI 0.11, 0.13]), those having least contact with others compared to those having the most (PPD 0.08 [95% CI 0.06, 0.09]), and individuals reporting no one to talk to compared to those reporting often having someone to talk to (PPD 0.08 [95% CI 0.06, 0.09]). The PPDs were lower, but still statistically significant, when comparing immigrants to individuals of Danish origin (PPD 0.04 [95% CI 0.02, 0.06]), and individuals living with other adults to those living alone or with younger children (PPD 0.03 [95% CI 0.03, 1.04]). Those with healthcare education did not have a significantly higher prevalence proportion difference compared to individuals without (PPD 0.01 [95% CI 0.00, 0.02]).

Table 3. PIM prevalence and adjusted prevalence proportion difference.

Characteristics Any PIM START PIM STOPP PIM
Count Mean SD Adj. PPD (95% CI) Count Mean SD Adj. PPD (95% CI) Count Mean SD Adj. PDD (95% CI)
All 39,970 0.23 0.63 33,990 0.19 0.58 5,980 0.03 0.19
Wealth quintile categories 1 (least) 7,325 0.21 0.6 0.12 (0.11, 0.13) 5,991 0.17 0.55 0.03 (0.00, 0.07) 1,334 0.04 0.2 0.03 (0.03, 0.03)
2 7,820 0.22 0.62 0.09 (0.08, 0.10) 6,521 0.18 0.56 0.01 (-0.02, 0.04) 1,299 0.04 0.21 0.02 (0.02, 0.03)
3 7,132 0.2 0.6 0.05 (0.04, 0.06) 6,016 0.17 0.55 -0.02 (-0.06, 0.01) 1,116 0.03 0.18 0.01 (0.01, 0.02)
4 8,161 0.23 0.64 0.03 (0.02, 0.04) 7,065 0.2 0.6 -0.01 (-0.04, 0.02) 1,096 0.03 0.19 0.01 (0.00, 0.01)
5 (most) 9,516 0.27 0.68 0 (Reference) 8,383 0.24 0.64 0 (Reference) 1,133 0.03 0.19 0 (Reference)
Income quintile categories 1 (least) 11,070 0.31 0.73 0.10 (0.09, 0.11) 9,300 0.26 0.67 0.00 (−0.03, 0.04) 1,770 0.05 0.24 0.03 (0.02, 0.03)
2 10,344 0.29 0.71 0.08 (0.07, 0.08) 8,750 0.25 0.65 0.00 (−0.04, 0.03) 1,594 0.04 0.23 0.02 (0.02, 0.02)
3 7,079 0.2 0.59 0.04 (0.03, 0.05) 6,071 0.17 0.55 0.00 (−0.04, 0.04) 1,008 0.03 0.18 0.01 (0.01, 0.01)
4 6,018 0.17 0.55 0.03 (0.02, 0.03) 5,157 0.15 0.52 0.03 (−0.01, 0.07) 861 0.02 0.16 0.00 (0.00, 0.01)
5 (most) 5,459 0.15 0.52 0 (Reference) 4,712 0.13 0.49 0 (Reference) 747 0.02 0.15 0 (Reference)
Immigration status Immigrant 173 0.12 0.44 0.04 (0.02, 0.06) 156 0.11 0.42 0.13 (0.00, 0.26) 17 0.01 0.11 0.00 (0.00, 0.01)
Descendant 1,942 0.16 0.55 0.00 (−0.01, 0.01) 1,694 0.14 0.52 0.11 (0.05, 0.16) 248 0.02 0.15 0.00 (−0.01, 0.00)
Danish origin 37,855 0.23 0.64 0 (Reference) 32,140 0.2 0.59 0 (Reference) 5,715 0.03 0.2 0 (Reference)
Household education level Primary and lower secondary 9,176 0.38 0.79 0.09 (0.07, 0.10) 7,596 0.31 0.73 −0.02 (−0.07, 0.02) 1,580 0.06 0.27 0.03 (0.02, 0.03)
Upper secondary 18,355 0.24 0.64 0.05 (0.04, 0.05) 15,641 0.2 0.59 0.00 (−0.04, 0.04) 2,714 0.03 0.2 0.01 (0.01, 0.01)
Tertiary/bachelor 9,023 0.18 0.56 0.02 (0.01, 0.02) 7,792 0.15 0.52 0.01 (−0.03, 0.06) 1,231 0.02 0.17 0.00 (0.00, 0.00)
Master/doctoral 2,995 0.13 0.49 0 (Reference) 2,602 0.11 0.46 0 (Reference) 393 0.02 0.14 0 (Reference)
Healthcare education No 24,248 0.2 0.59 0.01 (0.00, 0.02) 20,867 0.17 0.55 0.02 (−0.04, 0.07) 3,381 0.03 0.18 0.00 (−0.01, 0.00)
Yes 1,924 0.18 0.57 0 (Reference) 1,594 0.15 0.53 0 (Reference) 330 0.03 0.19 0 (Reference)
Social network 1 (infrequent) 2,411 0.32 0.75 0.08 (0.06, 0.09) 1,963 0.26 0.68 0.04 (−0.01, 0.10) 448 0.06 0.26 0.03 (0.02, 0.03)
2 11,401 0.24 0.65 0.02 (0.01, 0.03) 9,679 0.2 0.6 0.03 (0.00, 0.06) 1,722 0.04 0.2 0.00 (0.00, 0.01)
3 17,606 0.22 0.61 0.00 (0.00, 0.01) 15,090 0.19 0.57 0.02 (−0.02, 0.05) 2,516 0.03 0.19 0.00 (0.00, 0.00)
4 (frequent) 5,417 0.19 0.57 0 (Reference) 4,669 0.16 0.53 0 (Reference) 748 0.03 0.17 0 (Reference)
Cohabitation No 10,507 0.31 0.74 0.03 (0.03, 0.04) 8,779 0.26 0.68 0.03 (0.00, 0.05) 1,728 0.05 0.24 0.01 (0.01, 0.02)
Yes 26,404 0.2 0.59 0 (Reference) 22,665 0.17 0.55 0 (Reference) 3,739 0.03 0.18 0 (Reference)
Social support Never or almost never 2,136 0.31 0.75 0.08 (0.06, 0.09) 1,770 0.25 0.68 0.07 (0.02, 0.12) 366 0.05 0.25 0.02 (0.02, 0.03)
Sometimes 3,716 0.25 0.67 0.06 (0.05, 0.07) 3,077 0.21 0.62 0.08 (0.03, 0.12) 639 0.04 0.22 0.02 (0.01, 0.02)
Mostly 9,571 0.23 0.64 0.02 (0.01, 0.03) 8,133 0.19 0.59 0.05 (0.02, 0.08) 1,438 0.03 0.2 0.00 (0.00, 0.01)
Always 22,356 0.22 0.61 0 (Reference) 19,196 0.19 0.57 0 (Reference) 3,160 0.03 0.19 0 (Reference)

CI, confidence interval; PIM, potentially inappropriate medication; PPD, prevalence proportion differences; SD, standard deviation.

Adjusted for age and sex.

Association between PIM and economic, cultural, and social capital

When analyzing the ORs, we found that all variables for social position except health education were associated with PIM with a dose-response pattern after adjusting for age and sex (Fig 1, model 1a).

Fig 1. The OR for exposure to PIM (model 1a) and the prevalence proportion ratio for the exposure to increased number of PIMs (model 1b) between indicators of social position.

Fig 1

Legend text: PIM(s), potentially inappropriate medication(s); OR, odds ratio, PPR, prevalence proportion ratio; Ref., Reference, CI, confidence interval. Adjusted for age and sex.

Economic, cultural, and social capital

An inverse dose-response association was seen between economic capital and PIM. The groups with the least economic capital had 85% higher odds for PIM compared to the group with the most economic capital (wealth OR: 1.85 [95% CI 1.77, 1.94], income OR: 1.78 [95% CI 1.69, 1.87]) after adjusting for age and sex (Fig 1, model 1a). Among the indicators of cultural capital, the strongest dose-response association with PIM was seen for the highest attained education level in the household (OR: 1.66 [95% CI 1.56, 1.76] for primary/lower secondary school compared to master/doctoral) (Fig 1, model 1a). Social capital had the least substantial association with the odds for PIM compared to the other types of capital. Among the indicators of social capital, social support and social network demonstrated similar dose-response associations with PIM when adjusted for age and sex (never versus often and least versus most OR: 1.35 [95% CI 1.26, 1.44 and 1.26, 1.45]) (Fig 1, model 1a). The association between indicators of social position and the number of PIMs, given that individuals received at least 1 PIM, was not clinically relevant (Fig 1, model 1b).

Undertreatment and versus overtreatment, males versus females

Exploring the odds ratio for receiving PIM between different indicators of low social position, stratified by STOPP and START PIM, we found that STOPP PIM drove the overall associations. The associations were similar but stronger for STOPP PIM compared to the combined measure for PIM (Fig 2, model 2b versus Fig 1, model 1a). For START PIM (Fig 2, model 2a), a weak association was seen, besides slightly increased odds among descendants compared to individuals of Danish origin (OR: 1.25 [95% CI 1.12, 1.42]) and adverse association for education level and income with odds for START PIM (education OR: 0.79 [95% CI 0.71, 0.88] primary/lower secondary school compared to master/doctoral). This indicates that the odds for undertreatment may increase with increased education level.

Fig 2. The OR for exposure to START PIM (model 2a) and STOPP PIM (model 2b) between indicators of social position.

Fig 2

PIM, potentially inappropriate medication; OR, odds ratio; Ref., Reference; CI, confidence interval. Adjusted for age and sex.

Stratifying the START/STOPP analysis (Fig 2) by sex, we found that the capital form most dominant in STOPP PIM association differed between men and women (Fig 3). While men demonstrated a stronger association for economic capital (Fig 3, model 3b), women had a stronger association for cultural and social capital (Fig 3, model 3b). Interestingly, having a healthcare-related education, which has been insignificant in all other analyses, appeared to be strongly associated with STOPP PIM among men (OR: 0.58 [CI 95% 0.45, 0.76]).

Fig 3. The sex-stratified odds ratio for exposure to START PIM (model 3a) and STOPP PIM (model 3b) between indicators of social position.

Fig 3

PIM, potentially inappropriate medication; OR, odds ratio; Ref., Reference; CI, confidence Interval. Adjusted for age.

Mediation by long-term conditions

When accounting for the differential disease risk (i.e., the indirect association mediated by long-term conditions) on the association between social position and PIM, we found that the associations were similar but attenuated both when analyzing PIM in general but also for STOPP PIM (Fig 4, model 4a and 4b). Overall, more than half of the association between PIM and social position was explained by differential disease risk for the most predominant associations, e.g., wealth, income, education, social network, cohabitation, and social support (Fig 3).

Fig 4. The odds ratio for exposure to PIM (model 4a) and STOPP PIM (model 4b) between indicators of social position unmediated by long-term conditions.

Fig 4

PIM, potentially inappropriate medication; OR, odds ratio; Ref., Reference; CI, confidence Interval. Adjusted for age and sex.

Discussion

Our results showed that low economic, cultural, and social capital were associated with exposure to PIM. All investigated variables for social position, except for having a healthcare education, demonstrated a significant association with increased PIM after adjustment for sex and age. A dose-response relationship was evident for most variables, indicating that lower social positions corresponded to higher PIM exposure. However, social position was not associated with the number of PIMs. The association between social position and PIM was primarily seen for the indicators of overtreatment (STOPP criteria). The most pronounced associations with increased PIM were found for individuals with the lowest levels of income, education, and wealth. Other significant factors included being an immigrant, having low social support, and having a limited social network. The sex-stratified analyses revealed that these associations were largely consistent across both men and women, although the magnitude of associations varied between sexes. While the number of long-term conditions mediated much of this relationship, the association between social position and PIM remained statistically significant for all indicators of social position, excluding healthcare education. These findings suggest social inequality in PIM exposure, persisting even after accounting for disparities in disease risk.

Our findings are consistent with prior research that has established associations between PIM use and various measures of social position, including living alone, income, and education attainment [3134]. However, our study reveals additional dimensions of social position that may contribute to disparities in medical treatment. Notably, we shed light on the significance of social capital, which is a frequently overlooked factor in epidemiological research on social inequalities, as education, income, and occupation are commonly used to define social position [35,36]. Particularly, low social support was associated with PIM, although much of the association was mediated by long-term conditions. Limited social network and living without other adults had little association with PIM after considering differential disease risk. This may indicate that social capital lies in the ability to utilize the available resources in one’s network rather than in the network itself.

This study found that wealth and income exhibited the strongest association with PIM, which seems unexpected within the context of a primarily free-of-charge universal healthcare system. For potentially omitted medicines (START PIMs), this may be explained by the fact that medication expenses are only fully reimbursed when exceeding a certain threshold (590 EUR over one year (2017)). However, our study suggests that potentially inappropriate medicines (STOPP PIMs) are the primary contributors to social inequality in PIM exposure. This indicates that inequality in medical treatment is likely more nuanced than individuals’ ability to pay for medicines. Drawing from Bourdieu’s work, social inequality is perpetuated through social interactions and power dynamics [37], emphasizing the complex and interconnected nature of the mechanisms behind unequal access to medical treatment.

This study provided an opportunity to explore PIM in the context of a wide range of complex interconnected factors. The epidemiological approach to managing the link between social position, long-term conditions, and PIM, inspired by directed acyclic graphs [26], strengthened the study and improved the accuracy and the ability to draw insightful conclusions. Moreover, the large nationally representative survey population provided information on social capital, and this data was individually linked with national registries to provide reliable data on the population’s demographic characteristics, long-term conditions, and social position. The extensive study population enhances the generalizability of the findings to the broader Danish population, potentially also to other countries with similar characteristics, e.g., healthcare and socioeconomic structures. Also, the theory-driven operationalization of social position allowed for a strong foundation for understanding the social processes underlying health inequalities [11].

Nonetheless, social inequality is a complex and entangled issue, and the nuances are difficult to fully capture. Some variables may have acted as mediators or moderators of the association, and the complex nature of the study increased the risk of reverse causation in the study. Moreover, residual confounding from age and long-term conditions may occur; all conditions were weighted equally as we had no data on disease severity. Furthermore, our results were based on drug redemption rather than drug prescription or adherence, preventing us from determining when the issue of PIM arises on the path from prescription to the patient. PIM is a valid concept on a population level, but for the individual patient, there may be a good reason for prescribing and taking the medication despite the risk of adverse effects. For example, some patients may choose to continue taking a long-term nonsteroidal anti-inflammatory drug to relieve pain despite the potential risk of gastrointestinal and cardiovascular complications. Finally, our study population was based on survey respondents, and varying response rates might have introduced selection bias, potentially affecting the internal and external validity of the results.

Our findings underscore that social inequality in medical treatment remains a critical concern for the quality of care and the safety of medicine use, even in a universal free-of-charge healthcare system, on a national scale and after accounting for age, sex, and differential disease risk. Differences in patient behavior will possibly explain some of the associations. For example, patients with different social positions vary in their capacity to engage in shared decision-making on treatments [38]. However, we must acknowledge that such treatment inequalities could be attributable to the healthcare system and providers, including poor treatment quality, implicit provider biases, limited continuity of care, organizational barriers, or other structural factors [3941]. Moreover, lowering the healthcare access threshold is crucial to equitable use of healthcare services. Access to healthcare may relate to approachability, acceptability, availability and accommodation, affordability and appropriateness [42]. Addressing unequal medical treatment calls for a nuanced approach in order to provide better treatment for patients with the greatest needs. By acknowledging and addressing the impact of unequal treatment outcomes, we can strive to promote more equitable and effective patient care.

Social inequality in healthcare and treatment is not fully understood. In this study, we used PIM as an indicator of treatment quality. However, further investigations are needed to explore other indicators of treatment quality and the interplay between capitals to understand the underlying differences in the medical treatment of various social groups. For example, methods such as latent class analysis or cluster analysis could assist in identifying hidden groupings in exposure to poor medical treatment. Moreover, valuable insight could be gained from conducting similar research among populations underrepresented in research, e.g., homeless people or undocumented migrants.

This study showed that the individuals’ economic, cultural, and social capitals were highly associated with PIM, even after accounting for the disparities attributable to differential disease risk. The disparities were predominantly related to overtreatment rather than undertreatment and did not relate to the number of PIMs. Overall, economic capital exhibited the strongest association with PIM, followed by cultural and social capital. It is necessary to consider the association between PIM and social position when designing interventions and providing services to improve the quality of treatment and patient safety.

Supporting information

S1 Table. The RECORD statement.

(PDF)

pmed.1004473.s001.pdf (197.3KB, pdf)
S2 Table. Response rates in the Danish National Health Survey 2017.

(PDF)

pmed.1004473.s002.pdf (200.2KB, pdf)
S3 Table. Missing data.

(PDF)

pmed.1004473.s003.pdf (253.7KB, pdf)
S4 Table. PIM criteria definitions according to the register-adapted STOPP/START criteria.

(PDF)

pmed.1004473.s004.pdf (538.3KB, pdf)
S5 Table. Description of operationalization of capital forms.

(PDF)

pmed.1004473.s005.pdf (484.2KB, pdf)
S6 Table. Long-term conditions in the Danish Multimorbidity Index.

(PDF)

pmed.1004473.s006.pdf (156.6KB, pdf)
S1 Fig. Illustration of variables with directed acyclic graph (DAG).

(PDF)

pmed.1004473.s007.pdf (540.1KB, pdf)

Acknowledgments

We kindly thank the survey participants and Lone Niedziella for proofreading.

The content is solely the authors’ responsibility and does not necessarily represent the official views of the funders.

Abbreviations

DAG

directed acyclic graph

GP

general practitioner

OR

odds ratio

PIM

potentially inappropriate medication

PPD

prevalence proportion difference

SD

standard deviation

Data Availability

The data supporting this study’s findings can be made available to authorized research institutions with collaborative agreements that grant access to the Danish registers through Statistics Denmark and the Danish Health Data Authority. The Danish National Health Survey data was obtained from a third party upon application to the National Steering Group. All interested researchers can apply for this data from the National Institute of Public Health, University of Southern Denmark. More information on access to data is available from Statistics Denmark [accessed on 2024 07-22]: https://www.dst.dk/en/TilSalg/Forskningsservice/Dataadgang.

Funding Statement

APa received research grants from the Research Foundation for General Practice (EMN-2018-02975/160-822307, link: https://rltn.dk/fonde/praksisfondene/fonden-for-almen-praksis/), and the Graduate School of Health at Aarhus University (No. 160-780513, link: https://phd.health.au.dk/application/how-to-finance-a-phd). The funding was awarded after peer review of a research proposal. Subsequently, the funders played no role in the analysis, presentation, or interpretation of study results. The Danish National Health Survey was funded by The Capital Region, Region Zealand, The South Denmark Region, The Central Denmark Region, The North Denmark Region, Ministry of Health and the National Institute of Public Health, University of Southern Denmark.

References

  • 1.Chowdhury SR, Chandra Das D, Sunna TC, Beyene J, Hossain A. Global and regional prevalence of multimorbidity in the adult population in community settings: a systematic review and meta-analysis. EClinicalMedicine. 2023;57:101860. Epub 20230216. doi: 10.1016/j.eclinm.2023.101860 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. Epub 20171010. doi: 10.1186/s12877-017-0621-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Corsonello A, Onder G, Abbatecola AM, Guffanti EE, Gareri P, Lattanzio F. Explicit criteria for potentially inappropriate medications to reduce the risk of adverse drug reactions in elderly people: from Beers to STOPP/START criteria. Drug Saf. 2012;35(Suppl 1):21–28. doi: 10.1007/BF03319100 . [DOI] [PubMed] [Google Scholar]
  • 4.Perez T, Moriarty F, Wallace E, McDowell R, Redmond P, Fahey T. Prevalence of potentially inappropriate prescribing in older people in primary care and its association with hospital admission: longitudinal study. BMJ. 2018;363:k4524. Epub 20181114. doi: 10.1136/bmj.k4524 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Mackenbach JP, Rubio Valverde J, Bopp M, Bronnum-Hansen H, Costa G, Deboosere P, et al. Progress against inequalities in mortality: register-based study of 15 European countries between 1990 and 2015. Eur J Epidemiol. 2019;34(12):1131–42. Epub 20191115. doi: 10.1007/s10654-019-00580-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Farkas Z. Social Position and Social Status: An Institutional and Relational Sociological Conception. Hum Stud. 2022;45(3):417–445. doi: 10.1007/s10746-022-09640-8 [DOI] [Google Scholar]
  • 7.Nunes BP, Thume E, Tomasi E, Duro SM, Facchini LA. Socioeconomic inequalities in the access to and quality of health care services. Rev Saude Publica. 2014;48(6):968–976. doi: 10.1590/S0034-8910.2014048005388 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Khatter A, Moriarty F, Ashworth M, Durbaba S, Redmond P. Prevalence and predictors of potentially inappropriate prescribing in middle-aged adults: a repeated cross-sectional study. Br J Gen Pract. 2021;71(708):e491–e7. Epub 20210624. doi: 10.3399/BJGP.2020.1048 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Thorell K, Skoog J, Zielinski A, Borgquist L, Halling A. Licit prescription drug use in a Swedish population according to age, gender and socioeconomic status after adjusting for level of multi-morbidity. BMC Public Health. 2012;12:575. Epub 20120731. doi: 10.1186/1471-2458-12-575 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Qi Y, Vrooman JC, Almansa J, Ots P, Brouwer S, Reijneveld SA. A capital-based approach to better understand health inequalities: Theoretical and empirical explorations. SSM Popul Health. 2023;21:101309. Epub 20221205. doi: 10.1016/j.ssmph.2022.101309 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.McCartney G, Bartley M, Dundas R, Katikireddi SV, Mitchell R, Popham F, et al. Theorising social class and its application to the study of health inequalities. SSM Popul Health. 2019;7:015–15. Epub 20181102. doi: 10.1016/j.ssmph.2018.10.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Spiers GF, Liddle JE, Stow D, Searle B, Whitehead IO, Kingston A, et al. Measuring older people’s socioeconomic position: a scoping review of studies of self-rated health, health service and social care use. J Epidemiol Community Health. 2022;76(6):572–9. Epub 20220315. doi: 10.1136/jech-2021-218265 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Bourdieu P. Forms of Capital. In: Richardson JG, editor. Handbook of theory and research for the sociology of education. Westport, Conn: Greenwood Press; 1986. [Google Scholar]
  • 14.Paccoud I, Nazroo J, Leist A. A Bourdieusian approach to class-related inequalities: the role of capitals and capital structure in the utilisation of healthcare services in later life. Sociol Health Illn. 2020;42(3):510–25. Epub 20191125. doi: 10.1111/1467-9566.13028 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Bourdieu P. Language and Symbolic Power. Cambridge, Mass 1991.
  • 16.Pasgaard AA, Maehlisen MH, Overgaard C, Ejlskov L, Torp-Pedersen C, Boggild H. Social capital and frequent attenders in general practice: a register-based cohort study. BMC Public Health. 2018;18(1):310. Epub 20180302. doi: 10.1186/s12889-018-5230-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Bourdieu P. The Forms of Capital. Readings in Economic Sociology. 2002:280–91. doi: 10.1002/9780470755679.ch15 [DOI] [Google Scholar]
  • 18.Boserup SH, Kopczuk W, Kreiner CT. Born with a Silver Spoon? Danish Evidence on Wealth Inequality in Childhood. Econ J. 2018;128(612):F514–F544. doi: 10.1111/ecoj.12496 [DOI] [Google Scholar]
  • 19.Erlangsen A, Fedyszyn I. Danish nationwide registers for public health and health-related research. Scand J Public Health. 2015;43(4):333–9. Epub 20150310. doi: 10.1177/1403494815575193 . [DOI] [PubMed] [Google Scholar]
  • 20.Christensen AI, Lau CJ, Kristensen PL, Johnsen SB, Wingstrand A, Friis K, et al. The Danish National Health Survey: Study design, response rate and respondent characteristics in 2010, 2013 and 2017. Scand J Public Health. 2022;50(2):180–8. Epub 20201108. doi: 10.1177/1403494820966534 . [DOI] [PubMed] [Google Scholar]
  • 21.Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med. 2015;12(10):e1001885. Epub 20151006. doi: 10.1371/journal.pmed.1001885 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Jensen HAR, Lau CJ, Davidsen M, Feveile HB, Christensen AI, Ekholm O. The impact of non-response weighting in health surveys for estimates on primary health care utilization. Eur J Public Health. 2022;32(3):450–455. doi: 10.1093/eurpub/ckac032 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213–8. Epub 20141016. doi: 10.1093/ageing/afu145 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Ribe AR, Christensen LD, Vestergaard CH, Prior A, Brynningsen PK, Bro F, et al. Potentially inappropriate medications (PIMs): frequency and extent of GP-related variation in PIMs: a register-based cohort study. BMJ Open. 2021;11(7):e046756. Epub 20210714. doi: 10.1136/bmjopen-2020-046756 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Prior A, Vestergaard CH, Vedsted P, Smith SM, Virgilsen LF, Rasmussen LA, et al. Healthcare fragmentation, multimorbidity, potentially inappropriate medication, and mortality: a Danish nationwide cohort study. BMC Med. 2023;21(1):305. Epub 20230815. doi: 10.1186/s12916-023-03021-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Tennant PWG, Murray EJ, Arnold KF, Berrie L, Fox MP, Gadd SC, et al. Use of directed acyclic graphs (DAGs) to identify confounders in applied health research: review and recommendations. Int J Epidemiol. 2021;50(2):620–632. doi: 10.1093/ije/dyaa213 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Xu Z, Liang X, Zhu Y, Lu Y, Ye Y, Fang L, et al. Factors associated with potentially inappropriate prescriptions and barriers to medicines optimisation among older adults in primary care settings: a systematic review. Fam Med. Community Health. 2021;9(4). doi: 10.1136/fmch-2021-001325 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Prior A, Fenger-Gron M, Larsen KK, Larsen FB, Robinson KM, Nielsen MG, et al. The Association Between Perceived Stress and Mortality Among People With Multimorbidity: A Prospective Population-Based Cohort Study. Am J Epidemiol. 2016;184(3):199–210. Epub 20160711. doi: 10.1093/aje/kwv324 . [DOI] [PubMed] [Google Scholar]
  • 29.Act on Research Ethics Review of Health Research Projects (§ 14), Pub. L. No. 593(2018).
  • 30.WMA Declaration of Helsinki–Ethical Principles for Medical Research Involving Human Subjects. 2013. [PubMed]
  • 31.Bongue B, Naudin F, Laroche ML, Galteau MM, Guy C, Gueguen R, et al. Trends of the potentially inappropriate medication consumption over 10 years in older adults in the East of France. Pharmacoepidemiol Drug Saf 2009;18(12):1125–1133. doi: 10.1002/pds.1762 . [DOI] [PubMed] [Google Scholar]
  • 32.Doheny M, Schon P, Orsini N, Fastbom J, Burstrom B, Agerholm J. Socio-demographic differences in polypharmacy and potentially inappropriate drug use among older people with different care needs and in care settings in Stockholm, Sweden. Scand J Public Health. 2023;51(1):11–20. Epub 20210630. doi: 10.1177/14034948211018384 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Holmes HM, Luo R, Kuo YF, Baillargeon J, Goodwin JS. Association of potentially inappropriate medication use with patient and prescriber characteristics in Medicare Part D. Pharmacoepidemiol Drug Saf. 2013;22(7):728–34. Epub 20130314. doi: 10.1002/pds.3431 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Hwang J, Lyu B, Ballew S, Coresh J, Grams ME, Couper D, et al. The association between socioeconomic status and use of potentially inappropriate medications in older adults. J Am Geriatr Soc. 2023;71(4):1156–66. Epub 20221213. doi: 10.1111/jgs.18165 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Liberatos P, Link BG, Kelsey JL. The measurement of social class in epidemiology. Epidemiol Rev. 1988;10(1):87–121. doi: 10.1093/oxfordjournals.epirev.a036030 . [DOI] [PubMed] [Google Scholar]
  • 36.Galobardes B, Shaw M, Lawlor DA, Lynch JW, Davey Smith G. Indicators of socioeconomic position (part 1). J Epidemiol Community Health. 2006;60(1):7–12. Epub 2005/12/20. doi: 10.1136/jech.2004.023531 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Bourdieu P, Wacquant LJ. An invitation to reflexive sociology: Polity Cambridge; 1992.
  • 38.Verlinde E, De Laender N, De Maesschalck S, Deveugele M, Willems S. The social gradient in doctor-patient communication. Int J Equity Health. 2012;11:12. Epub 20120312. doi: 10.1186/1475-9276-11-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Nwadiugwu MC. Multi-Morbidity in the Older Person: An Examination of Polypharmacy and Socioeconomic Status. Front Public Health. 2020;8:582234. Epub 20210118. doi: 10.3389/fpubh.2020.582234 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Spencer KL, Grace M. Social Foundations of Health Care Inequality and Treatment Bias. Annu Rev Sociol. 2016;42(1):101–120. doi: 10.1146/annurev-soc-081715-074226 [DOI] [Google Scholar]
  • 41.Dubbin LA, Chang JS, Shim JK. Cultural health capital and the interactional dynamics of patient-centered care. Soc Sci Med. 2013;93:113–20. Epub 20130622. doi: 10.1016/j.socscimed.2013.06.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Levesque JF, Harris MF, Russell G. Patient-centred access to health care: conceptualising access at the interface of health systems and populations. Int J Equity Health. 2013;12:18. Epub 20130311. doi: 10.1186/1475-9276-12-18 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Philippa C Dodd

20 Dec 2023

Dear Dr Paust,

Thank you for submitting your manuscript entitled "Economic, cultural, and social inequalities in potentially inappropriate medication: a nationwide survey- and register-based study" for consideration by PLOS Medicine.

Your manuscript has now been evaluated by the PLOS Medicine editorial staff and I am writing to let you know that we would like to send your submission out for external peer review.

However, before we can send your manuscript to reviewers, we need you to complete your submission by providing the metadata that is required for full assessment. To this end, please login to Editorial Manager where you will find the paper in the 'Submissions Needing Revisions' folder on your homepage. Please click 'Revise Submission' from the Action Links and complete all additional questions in the submission questionnaire.

Please re-submit your manuscript within two working days, i.e. by Dec 22 2023 11:59PM.

Login to Editorial Manager here: https://www.editorialmanager.com/pmedicine

Once your full submission is complete, your paper will undergo a series of checks in preparation for peer review. Once your manuscript has passed all checks it will be sent out for review.

Feel free to email me at pdodd@plos.org or the team at plosmedicine@plos.org if you have any queries relating to your submission.

Kind regards,

Pippa

Philippa Dodd, MBBS MRCP PhD

PLOS Medicine

Decision Letter 1

Philippa C Dodd

13 Mar 2024

Dear Dr. Paust,

Many thanks for submitting your manuscript "Economic, cultural, and social inequalities in potentially inappropriate medication: a nationwide survey- and register-based study PMEDICINE-D-23-03737R1” to PLOS Medicine. The paper has been reviewed by two subject experts and a statistician; their comments are included below and can also be accessed here: [LINK]

As you will see, the reviewers were very positive about the paper but, they raised a number of questions about specific study details and the methodological approach. After discussing the paper with the editorial team and an academic editor with relevant expertise, I’m pleased to invite you to revise the paper in response to the reviewers’ comments. We plan to send the revised paper to some of all of the original reviewers*, and of course we cannot provide any guarantees at this stage regarding publication.

When you upload your revision, please include a point-by-point response that addresses all of the reviewer and editorial points, indicating the changes made in the manuscript and either an excerpt of the revised text or the location (eg: page and line number) where each change can be found. Please submit a clean version of the paper as the main article file and a version with changes marked should as a marked-up manuscript. Please also check the guidelines for revised papers at http://journals.plos.org/plosmedicine/s/revising-your-manuscript for any that apply to your paper.

We ask that you submit your revision by April 3rd 2024. However, if this deadline is not feasible, please contact me by email, and we can discuss a suitable alternative.

Please don’t hesitate to contact me directly with any questions (pdodd@plos.org). If you reply directly to this message, please be sure to ‘Reply All’ so your message comes directly to my inbox.

Kind regards,

Pippa

Philippa Dodd MBBS MRCP PhD

PLOS Medicine

plosmedicine.org

pdodd@plos.org

*Please note: If your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

-----------------------------------------------------------

Editorial comments:

1) It took rather a long time to secure reviewers for your manuscript and we thank you for your patience. We agree with the reviewers and with the academic editor that your manuscript could be further strengthened and request that you respond to all comments in full.

2) We agree that stratifying your analyses by sex would be a very valuable and we agree that investigating STOPP and START separately would also add additional insights and nuance. Please amend accordingly.

3) We agree with the statistical reviewer that reporting your study according to RECORD would be appropriate. Please see here for further details https://www.equator-network.org/reporting-guidelines/record/. When completing the checklist, please use section and paragraph numbers, rather than page numbers as these often change in event of publication.

4) For all observational studies we request that in the manuscript text, you please indicate: (1) the specific hypotheses you intended to test, (2) the analytical methods by which you planned to test them, (3) the analyses you actually performed, and (4) when reported analyses differ from those that were planned, transparent explanations for differences that affect the reliability of the study's results. If a reported analysis was performed based on an interesting but unanticipated pattern in the data, please be clear that the analysis was data-driven.

5) Did your study have a prospective protocol or analysis plan? Please state this (either way) early in the Methods section.

a) If a prospective analysis plan (from your funding proposal, IRB or other ethics committee submission, study protocol, or other planning document written before analyzing the data) was used in designing the study, please include the relevant prospectively written document with your revised manuscript as a Supporting Information file to be published alongside your study, and cite it in the Methods section. A legend for this file should be included at the end of your manuscript.

b) If no such document exists, please make sure that the Methods section transparently describes when analyses were planned, and when/why any data-driven changes to analyses took place.

c) In either case, changes in the analysis-- including those made in response to peer review comments-- should be identified as such in the Methods section of the paper, with rationale.

-----------------------------------------------------------

Comments from the reviewers:

Reviewer #1: See attachment

Michael Dewey

Reviewer #2: This is an interesting manuscript, aiming to divulge more of the hard to define concept social position and its relation to health inequalities.

The article looks at potentially inappropriate medication (PIM) and social inequality. By using Bourdieu´s capital theory the authors are including not only economic and cultural capital but also social capital. By using individual answers from a household survey in combination with register data they are able to analyse the association between PIM and social inequality on an individual level.

They can confirm previous findings regarding social inequality expressed by economic and cultural capital and these findings are also detected regarding social capital, however weaker.

Despite this, I have a couple of remarks regarding the manuscript:

My main objection is that the results are not reported separately for men and women. Women utilize more health care and consume more medicine and in my mind, this is a fundamental reason to make a gender division.

Minor objections:

In the introduction where the authors outline social class and there will to analyse according to Bourdieu´s work no direct reference is made to his work, only indirect references. Although this reference is made in the supplement, it is appropriate to have it in the main text.

In the first section of the results section (descriptive) a textual briefing of table 2 is made. Unfortunately, the order in the briefing and the table are not equivalent. Better if the orders not are different.

In table 3, please check the count figures for wealth quintiles. It looks as if the order is wrong.

The authors have analysed each variable by its own but it would have been interesting to see some example of interaction, for example can high social capital compensate low economic capital.

All in all, I find this interesting not only for me but for a wider audience if corrections are made.

Reviewer #3: Thank you for the opportunity to review the manuscript. This is an interesting and novel study investigating the association between social position and quality of medication use. The research question and statistical analysis are generally well-defined and straight forward. The main limitation is that the theoretical framework is not sufficiently integrated and that the outcome and some analytical decisions should be further problematized/discussed.

Below, I list some issues that in my view, would improve the paper.

Main comments:

1. I am supportive of the authors decision to use more indicators than education/income/occupation to assess social position. However, I am a bit skeptical about the theoretical connection to Bourdieu's capital terminology. Although I am far from an expert on Bourdieu's work, I have some recommendation to potentially bridge the gap between the analysis and the theoretical discussion: First, the mechanisms underlying the associations as presented in the Discussion should be expanded. Currently, the presented mechanisms are largely materialistic and immediate in nature. In my mind, Bourdieu's work is more concentrated on how social stratification is transferred over time periods/generations and how the capital is used to distinguish/differentiate oneself in relation to other people. It is a bit hard to see how this relates to inappropriate medication use Second, including healthcare-related education as a form of Cultural capital fits well with the study at hand but is more unclear in relation to the term cultural capital in general, and should be better justified.

2. I have some comments relating to the selected outcome: a) Please provide a reference to the STOPP/START criteria, also indicating which version of STOPP/START you used. b) The STOPP/START criteria were developed specifically for older adults, because some medications that are appropriate in other age groups are inappropriate in older adults (e.g. NSAIDs). Hence, you will need to motivate the use of these criteria in other age groups. c) The START criteria are often not included in studies about medication quality, I would be interested to see the results for STOPP and START separately, also as there might be slightly different process generating inequality for the two different domains. d) It is clearly stated that the PIMs were calculated as a one-day point prevalence (which is a good decision especially for drug-drug interactions). However, I can not find information on the method used to calculate the one-day point prevalence, how long was the look-back period, was duration calculated using the DDD-method etc.?

3. The analytical decision to conduct mediation analysis to address long-term conditions should be better supported. I generally agree with the decision, but I think it could be more clearly stated what it is and what the benefits are.

Minor comments:

4. Does reference #5 really support the authors statement?

5. The category 'living alone or with child(ren)' is unclear and should be re-named.

6. I recommend removing "strongly" in the first sentence of the Discussion (Row 226)

Any attachments provided with reviews can be seen via the following link:

[LINK]

-----------------------------------------------------------

Comments from the Academic Editor:

Overall, I think it is quite well done but I think opportunities to make it quite strong. Happy to take a look after reviews are in or after authors respond to them.

This is a well-written article using a robust dataset. Epidemiological analyses are well-thought out and theoretically informed. A few suggestions for improvements to make analyses more robust.

-Consider differences between medications that should have been started but weren’t vs. not stopping a necessary medication. Particularly in terms of socioeconomic and racial disparities, access is substantial driver and will mostly affect whether necessary medication not started. I think I would be more interested in these separately rather than an aggregate measure as I think the mechanisms are likely quite different (quality itself is a broad construct and has many dimensions). Consider reporting each separately rather in aggregate.

-See Levesque et al framework on access. I think this can complement existing theoretical foundation and perhaps fine tune analysis/conceptualization. https://equityhealthj.biomedcentral.com/articles/10.1186/1475-9276-12-18.

-I am confused about adjusted risk differences presented. e.g., for wealth, it seems like mean increases as wealth goes goes up, but this is opposite of adjusted risk difference. Is it true the adjustment fully reversed direction of relationship?

-

I think it would be quite interesting to also consider interactions between different types of capital. E.g., lack of social capital may be particularly exacerbated in the presence of lack of economic capital. High economic capital may counteract impact of low social capital etc.

-I think there is also an element of who your contacts are. This may be captured in the interaction between social and economic capital (e.g., are you connect to well off and well connected individuals?). I imagine the data doesn’t actually capture this directly, but this could provide useful inferences.

-In truth, there may be complex interactions between the different type of capital that essentially identify different subgroups phenotypes. Although complicated to do, using latent class analysis with the different measures of social position to identify these phenotypes and then using this as the exposure would be quite interesting. Could think of other methods for segmentation as well.

-I think would be very helpful to think of ways to consider how these disparities are concentrated. Something like Lorenz curves, Gini index, concentration indices can help to understand how much of the disparities are concentrated at the extremes or whether they are more evenly distributed. Beyond the association, this could help understand where the public health burden really lies.

-What important measurement issues may be present? These are all hard concepts to actually measure and capture and probably worth some discussion.

-The use of DAGs in thinking through analyses for these complex phenomena is a strength. I would include these in the supplement so it is clear how each different analysis was conceptualized. This is important work that the authors have done which should be highlighted.

-----------------------------------------------------------

General editorial requests:

1. Please upload any figures associated with your paper as individual TIF or EPS files with 300dpi resolution at resubmission; please read our figure guidelines for more information on our requirements: http://journals.plos.org/plosmedicine/s/figures. While revising your submission, please upload your figure files to the PACE digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at PLOSMedicine@plos.org.

2. Please ensure that the paper adheres to the PLOS Data Availability Policy (see http://journals.plos.org/plosmedicine/s/data-availability), which requires that all data underlying the study's findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by "data not shown" or "unpublished results." For such statements, authors must provide supporting data or cite public sources that include it.

3. We ask every co-author listed on the manuscript to fill in a contributing author statement, making sure to declare all competing interests. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. If new competing interests are declared later in the revision process, this may also hold up the submission. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT. You can see our competing interests policy here: http://journals.plos.org/plosmedicine/s/competing-interests.

-----------------------------------------------------------

To submit your revised manuscript please use the following link:

https://www.editorialmanager.com/pmedicine/

Your article can be found in the "Submissions Needing Revision" folder.

Attachment

Submitted filename: paust.pdf

pmed.1004473.s008.pdf (63KB, pdf)

Decision Letter 2

Philippa C Dodd

12 Jul 2024

Dear Dr. Paust,

Thank you very much for re-submitting your manuscript "Economic, cultural, and social inequalities in potentially inappropriate medication: a nationwide survey- and register-based study in Denmark" (PMEDICINE-D-23-03737R2) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by 3 reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

[LINK]

***Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.***

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers' and editors' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at http://journals.plos.org/plosmedicine/s/revising-your-manuscript for any that apply to your paper. If you haven't already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (plosmedicine@plos.org) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see http://journals.plos.org/plosmedicine/s/data-availability), which requires that all data underlying the study's findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by "data not shown" or "unpublished results." For such statements, authors must provide supporting data or cite public sources that include it.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript.

Please note, when your manuscript is accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you've already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at plosmedicine@plos.org.

If you have any questions in the meantime, please contact me or the journal staff on plosmedicine@plos.org.  

We look forward to receiving the revised manuscript by Jul 19 2024 11:59PM.   

Kind regards,

Pippa

Philippa Dodd, MBBS MRCP PhD

Senior Editor 

PLOS Medicine

plosmedicine.org

------------------------------------------------------------

Requests from Editors:

GENERAL

Thank you for your very detailed and considered responses to previous editor and reviewer comments. Please respond to further comments detailed below prior to publication.

Many of the editorial requests pertain to specific content and formatting requirements, some may not apply and others may have already been incorporated into the manuscript but please review each item and maned as necessary.

We agree with the reviewer (please see below) regarding the inclusion of the sex disaggregated data within the main manuscript as opposed to supporting information. Please amend accordingly.

DATA AVAILABILITY STATEMENT

Please include a URL for Statistics Denmark and the Danish Health Data Authority for those wishing to apply for access to data.

ABSTRACT

Please structure your abstract using the PLOS Medicine headings (Background, Methods and Findings, Conclusions).

Please combine the Methods and Findings sections into one section, “Methods and findings”.

Abstract Background: Please provide context of why the study is important. The final sentence should clearly state the study question.

Abstract Background: Please provide context of why the study is important. The final sentence should clearly state the study question.

Abstract Methods and Findings:

Please ensure that all numbers presented in the abstract are present and identical to numbers presented in the main manuscript text.

Please include the study design, population and setting, number of participants, years during which the study took place, length of follow up, and main outcome measures.

Please quantify the main results with 95% CIs and p values.

Please include the important dependent variables that are adjusted for in the analyses.

Please include the actual amounts and/or absolute risk(s) of relevant outcomes (including NNT or NNH where appropriate), not just relative risks or correlation coefficients. (example for absolute risks: PMID: 28399126).

Please include a summary of adverse events if these were assessed in the study.

In the last sentence of the Abstract Methods and Findings section, please describe the main limitation(s) of the study's methodology.

Abstract Conclusions:

Please address the study implications without overreaching what can be concluded from the data; the phrase "In this study, we observed ..." may be useful.

Please interpret the study based on the results presented in the abstract, emphasizing what is new without overstating your conclusions.

Please avoid vague statements such as "these results have major implications for policy/clinical care". Mention only specific implications substantiated by the results.

Please avoid assertions of primacy ("We report for the first time....")

STATISTICAL REPORTING

Throughout, including tables and figures, please quantify the main results with 95% CIs and p values.

When reporting p values please report as <0.001 and where higher as p=0.002, for example. If not reporting p values, for the purpose of transparent data reporting, please clearly state the reasons why not. When reporting 95% CIs please separate upper and lower bounds with commas instead of hyphens as the latter can be confused with reporting of negative values.

Please include the actual amounts and/or absolute risk(s) of relevant outcomes (including NNT or NNH where appropriate), not just relative risks or correlation coefficients. (example for absolute risks: PMID: 28399126).

AUTHOR SUMMARY

Thank you for including an Author Summary which reads very nicely.

The author summary should immediately follow the Abstract in your revised manuscript. Please amend.

It would be helpful to provide a couple of examples of the ‘variables for social position’ that your refer to.

In the final bullet point of ‘What Do These Findings Mean?’, please describe the main limitations of the study in non-technical language.

Line 69 – pleas remove the sub-heading ‘Manuscript’.

INTRODUCTION

Please ensure that the introduction addresses past research and explain the need for and potential importance of your study. Indicate whether your study is novel and how you determined that. If there has been a systematic review of the evidence related to your study (or you have conducted one), please refer to and reference that review and indicate whether it supports the need for your study.

METHODS and RESULTS

Please report the number of [patients, samples, etc] and dates of recruitment, and account for all methods used in your study.

Please define "lost to follow-up" as used in this study. Other reasons for exclusion should be defined.

Please define the length of follow up (eg, in mean, SD, and range).

Please provide the actual numbers of events for the outcomes, not just summary statistics or ORs.

Please present numerators and denominators used to derive percentages.

Please ensure to indicate where analyses are adjusted and which factors are adjusted for.

As for the abstract, please ensure to quantify the main results with 95% CIs and p values.

When a p value is given, please specify the statistical test used to determine it.

As above please include the disaggregated data within the main manuscript.

TABLES and FIGURES

As above please include the disaggregated data within the main manuscript.

Please see here for guidelines on submitting and citing figures https://journals.plos.org/plosmedicine/s/figures#loc-how-to-submit-figures-and-captions

Please provide titles and legends for all tables and figures (including those in Supporting Information files).

Please ensure that each table and figure is affiliated to a caption which clearly describes the figure content without the need to refer to the text.

Please ensure that all abbreviations are defined in the caption or an appropriate footnote, including those used to report statistical information.

Please ensure to include the meaning of any dots/lines/bars.

Please consider avoiding the use of red and green in order to make figures more accessible to those with colour blindness.

To help facilitate transparent data reporting, where adjusted analyses are presented please also present the unadjusted analyses for comparison. In a caption or footnote please detail all factors adjusted for.

DISCUSSION

Please ensure to present and organize the Discussion as follows: a short, clear summary of the article's findings; what the study adds to existing research and where and why the results may differ from previous research; strengths and limitations of the study; implications and next steps for research, clinical practice, and/or public policy; one-paragraph conclusion. Please avoid the use of sub-headings such that the discussion reads as continuous prose.

Lines 347, 365 and 367 – please remove these statements from the main manuscript and include only in the manuscript submission form when you resubmit your manuscript. At the time of publication these will be compiled as metadata.

REFERENCES

For in-text reference callouts please place citations in square parentheses separate by commas. For example, [1,3,6] or [1-3]. Please check and amend throughout all sub-sections of the manuscript and supporting files.

In the bibliography please ensure that you list up to but no more than 6 author names followed by et al.

For all web references please ensure you include an, ‘Accessed [date].’

Journal name abbreviations should be those listed in the National Center for Biotechnology Information (NCBI) databases.

SUPPORTING INFORMATION

In the published article, supporting information files are accessed only through a hyperlink attached to the captions. For this reason, you must list captions at the end of your manuscript file. You may include a caption within the supporting information file itself, as long as that caption is also provided in the manuscript file. Do not submit a separate caption file.

As the supporting information files are contained with a single file, please label and cite the ‘supplementary appendices’ and ‘initial project description’ as follows:

Please label the files as ‘S1 Supplementary appendices’ and ‘S2 Study protocol and analysis plan’ respectively.

Please apply alphabetical labelling to each table and figure contained within the S1 file. For example, ‘Fig A’ to ‘Fig Z’ and ‘Table A’ to ‘Table Z’.

Plain text does not need to be labelled and can just be given a title as necessary. For example, ‘Statistical Analysis Plan’.

Please cite tables/figures as ‘Fig A in S1 Supplementary appendices’ and/or ‘Table A in S1 Supplementary appendices’, for example.

SOCIAL MEDIA

To help us extend the reach of your research, please detail any X (formerly Twitter) handles you wish to be included when we tweet this paper (including your own, your coauthors’, your institution, funder, or lab) in the manuscript submission form when you re-submit the manuscript.

Comments from Reviewers:

Reviewer #1: The authors have addressed all my points

Michael Dewey

Reviewer #2: Thank you for your revised manuscript. You have done a great job of meeting all reviewers' comments and the manuscript has now improved.

However, I do have a continuing remark regarding gender stratification:

I appreciate that the appendix now have separate tables and figures for women and men and, to stress my point, there are differences. Not many, but enough to mention in the results and discussion.

I agree that it is a lot of data but I would have preferred to have the gender stratified tables and figures in the main article, not in the appendix, but I leave this decision to the editor.

Also, maybe the interaction analysis would be too much for the main article, bur since you have performed the analysis, it would have been nice to see the results (gender stratified!) in the appendix.

Finally, eFigure 2 clarifies the difference between models a and b in the heading (START and STOP). This explanation would benefit the figures in the manuscript.

Reviewer #3: Thank you for the opportunity to review this manuscript again. The authors have done a great job revising the analytical and theoretical part of the manuscript. I have some minor comments that I think would improve an already well-developed manuscript.

Below, I list some issues that in my view, would improve the paper.

Minor comments:

1. The separation of PIMS into STOP and START have improved the paper substantially, I now agree with the analytical decisions. However, the authors should revise how they describe these results in the Result-section and in Discussion (under the heading key-finding) for style and clarity.

2. Row 327-329. I would argue that both gastrointestinal and cardiovascular complications are more recognized side-effects of long-term NSAID use in older adults. Consider changing.

Any attachments provided with reviews can be seen via the following link:

[LINK]

Decision Letter 3

Philippa C Dodd

6 Sep 2024

Dear Dr Paust, 

On behalf of my colleagues and the Academic Editor, Dr. Aaloke Mody, I am pleased to inform you that we have agreed to publish your manuscript "Economic, cultural, and social inequalities in potentially inappropriate medication: a nationwide survey- and register-based study in Denmark" (PMEDICINE-D-23-03737R3) in PLOS Medicine.

Prior to publication and at the time you complete your formatting changes as detailed below, please also include the RECORD checklist as supporting information. When completing the checklist please refer to section and paragraph numbers as opposed to page/line numbers as these often change at publication.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Once you have received these formatting requests, please note that your manuscript will not be scheduled for publication until you have made the required changes.

In the meantime, please log into Editorial Manager at http://www.editorialmanager.com/pmedicine/, click the "Update My Information" link at the top of the page, and update your user information to ensure an efficient production process. 

PRESS

We frequently collaborate with press offices. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximise its impact. If the press office is planning to promote your findings, we would be grateful if they could coordinate with medicinepress@plos.org. If you have not yet opted out of the early version process, we ask that you notify us immediately of any press plans so that we may do so on your behalf.

We also ask that you take this opportunity to read our Embargo Policy regarding the discussion, promotion and media coverage of work that is yet to be published by PLOS. As your manuscript is not yet published, it is bound by the conditions of our Embargo Policy. Please be aware that this policy is in place both to ensure that any press coverage of your article is fully substantiated and to provide a direct link between such coverage and the published work. For full details of our Embargo Policy, please visit http://www.plos.org/about/media-inquiries/embargo-policy/.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Thank you again for submitting to PLOS Medicine. We look forward to publishing your paper. 

Kind regards,

Pippa

Philippa C. Dodd, MBBS MRCP PhD 

Senior Editor 

PLOS Medicine

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. The RECORD statement.

    (PDF)

    pmed.1004473.s001.pdf (197.3KB, pdf)
    S2 Table. Response rates in the Danish National Health Survey 2017.

    (PDF)

    pmed.1004473.s002.pdf (200.2KB, pdf)
    S3 Table. Missing data.

    (PDF)

    pmed.1004473.s003.pdf (253.7KB, pdf)
    S4 Table. PIM criteria definitions according to the register-adapted STOPP/START criteria.

    (PDF)

    pmed.1004473.s004.pdf (538.3KB, pdf)
    S5 Table. Description of operationalization of capital forms.

    (PDF)

    pmed.1004473.s005.pdf (484.2KB, pdf)
    S6 Table. Long-term conditions in the Danish Multimorbidity Index.

    (PDF)

    pmed.1004473.s006.pdf (156.6KB, pdf)
    S1 Fig. Illustration of variables with directed acyclic graph (DAG).

    (PDF)

    pmed.1004473.s007.pdf (540.1KB, pdf)
    Attachment

    Submitted filename: paust.pdf

    pmed.1004473.s008.pdf (63KB, pdf)
    Attachment

    Submitted filename: Point-by-point review response_24_06_16.docx

    pmed.1004473.s009.docx (53.5KB, docx)
    Attachment

    Submitted filename: Review response_24_09_28.docx

    pmed.1004473.s010.docx (39.3KB, docx)

    Data Availability Statement

    The data supporting this study’s findings can be made available to authorized research institutions with collaborative agreements that grant access to the Danish registers through Statistics Denmark and the Danish Health Data Authority. The Danish National Health Survey data was obtained from a third party upon application to the National Steering Group. All interested researchers can apply for this data from the National Institute of Public Health, University of Southern Denmark. More information on access to data is available from Statistics Denmark [accessed on 2024 07-22]: https://www.dst.dk/en/TilSalg/Forskningsservice/Dataadgang.


    Articles from PLOS Medicine are provided here courtesy of PLOS

    RESOURCES